1. Canetti D, Riccardi N, Martini M, Villa S, Di Biagio A, Codecasa L, et al. HIV and tuberculosis: the paradox of dual illnesses and the challenges of their fighting in the history. Tuberculosis. 2020;122:1-4.

https://doi.org/10.1016/j.tube.2020.101921

PMid:32501257 

2. Sodré CS, Rodrigues PMG, Vieira MS, Marques Paes da Silva A, Gonçalves LS, Ribeiro MG, et al. Oral mycobiome identification in atopic dermatitis, leukemia, and HIV patients - a systematic review. J Oral Microbiol. 2020;12:1-19.

https://doi.org/10.1080/20002297.2020.1807179

PMid:32944157 PMCid:PMC7482892

3. Passos DF, Bremm JM, da Silveira LL, Jantsch MH, da Silva JLG, Disconzi E, et al. CD4/CD8 ratio, comorbidities, and aging in treated HIV infected individuals on viral suppression. J Med Virol. 2020.

https://doi.org/10.1002/jmv.25911

PMid:32314818 

4. Patil S, Majumdar B, Sarode SC, Sarode GS, Awan KH. Oropharyngeal Candidosis in HIV-Infected Patients-An Update. Front Microbiol. 2018;9:980.

https://doi.org/10.3389/fmicb.2018.00980

PMid:29867882 PMCid:PMC5962761

5. Mumtaz GR, Riedner G, Abu-Raddad LJ. The emerging face of the HIV epidemic in the Middle East and North Africa. Curr Opin HIV AIDS. 2014;9:183-91.

https://doi.org/10.1097/COH.0000000000000038

PMid:24445372 PMCid:PMC3921267

6. Hübel K. The changing landscape of lymphoma associated with HIV infection. Curr Oncol Rep. 2020;22:111.

https://doi.org/10.1007/s11912-020-00973-0

PMid:32803474 PMCid:PMC8302507

7. Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. New Engl J Med. 2018;378:1029-41.

https://doi.org/10.1056/NEJMra1615896

PMid:29539283 PMCid:PMC6890231

8. Mahale P, Ugoji C, Engels EA, Shiels MS, Peprah S, Morton LM. Cancer risk following lymphoid malignancies among HIV-infected people. AIDS. 2020;34:1237-45.

PMid:32287068 PMCid:PMC7382023

9. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90.

https://doi.org/10.1182/blood-2016-01-643569

PMid:26980727 PMCid:PMC4874220

10. Taiwo OO, Hassan Z. The impact of Highly Active Antiretroviral Therapy (HAART) on the clinical features of HIV - related oral lesions in Nigeria. AIDS Res Ther. 2010;7:19.

https://doi.org/10.1186/1742-6405-7-19

PMid:20579347 PMCid:PMC2903493

11. Alli N, Meer S. Head and neck lymphomas: a 20-year review in an oral pathology unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS. Oral Oncol. 2017;67:17-23.

https://doi.org/10.1016/j.oraloncology.2017.01.011

PMid:28351573 

12. Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:571-8.

https://doi.org/10.1016/j.tripleo.2005.01.015

PMid:16243242 

13. Boy SC, Heerden MB, Babb C, van Heerden WF, Willem P. Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas. Oral Oncol. 2011;47:883-7.

https://doi.org/10.1016/j.oraloncology.2011.06.506

PMid:21783402 

14. Corti M, Villafañe MF, Solari R, De Carolis L, Cangelosi D, Santoro J. Non-Hodgkin lymphomas of the oral cavity in AIDS patients in a reference hospital of infectious diseases in Argentina: report of eleven cases and review of the literature. Gastrointest Cancer. 2011;42:143-8.

https://doi.org/10.1007/s12029-010-9173-9

PMid:20563896 

15. Wu J, Miao Y, Qian C, Tao P, Wang X, Dong X, et al. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: a retrospective single-center study. J Cancer. 2021;12:2903-11.

https://doi.org/10.7150/jca.51027

PMid:33854591 PMCid:PMC8040883

16. Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-9.

https://doi.org/10.1158/1055-9965.EPI-11-0777

PMid:22109347 PMCid:PMC3237725

17. Shepherd L, Ryom L, Law M, Hatleberg CI, de Wit S, Monforte AD, et al. Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma. J Natl Cancer Inst. 2018;110:598-607.

https://doi.org/10.1093/jnci/djx249

PMid:29267895 PMCid:PMC6693037

18. Hoffmann C, Hentrich M, Gillor D, Behrens G, Jensen B, Stoehr A, et al. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study. HIV Med. 2015;16:261-4.

https://doi.org/10.1111/hiv.12200

PMid:25252101 

19. Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, et al. Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV. 2019;6:e240-e9.

PMid:30826282

20. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28:453-65.

https://doi.org/10.1097/QAD.0000000000000071

PMid:24401642 PMCid:PMC4501859

21. Hijlkema SH, van Kampen JJA, Voermans JJC, den Oudsten MYE, Doorduijn J, van Lugtenburg PJ, et al. A longitudinal and cross-sectional study of Epstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients. Infect Disease. 2018;50:847-52.

https://doi.org/10.1080/23744235.2018.1508884

PMid:30317893 

22. Fernandes CIR, Souza LLS, Costa SFS, Silva AMBS, Pontes HAR, Lopes MA, et al. Clinicopathological analysis of oral plasmablastic lymphoma: a systematic review. J Oral Pathol Med. 2018;47:915-22.

https://doi.org/10.1111/jop.12753

PMid:29917262 

23. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma. 2010;51:2047-53.

https://doi.org/10.3109/10428194.2010.516040

PMid:20919850 

24. Tanaka PY, Pracchia LF, Bellesso M, Chamone DAF, Calore EE, Pereira J. A prognostic score for AIDS-related diffuse large B-cell lymphoma in Brazil. Ann Hematol. 2010;89:45-51.

https://doi.org/10.1007/s00277-009-0761-3

PMid:19495752 

25. Chao C, Silverberg MJ, Martínez-Maza O, Chi M, Abrams DI, Haque R, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma. Clin Cancer Res. 2012;18:4702-12.

https://doi.org/10.1158/1078-0432.CCR-11-3169

PMid:22711707 PMCid:PMC3846529

26. Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372:20160271.

https://doi.org/10.1098/rstb.2016.0271

PMid:28893938 PMCid:PMC5597738

27. Silva WF, Garibaldi PMM, Rosa LI, Bellesso M, Clé DV, Delamain MT, et al. Outcomes of HIV-associated Burkitt lymphoma in Brazil: high treatment toxicity and refractoriness rates - a multicenter cohort study. Leuk Res. 2020;89:106287.

https://doi.org/10.1016/j.leukres.2019.106287

PMid:31864677 

28. Argyris PP, Dolan M, Piperi E, Tosios KI, Pambuccian SE, Koutlas IG. Oral follicular lymphomas. A short report of 8 cases with assessment of the IGH/BCL2 gene fusion with fluorescence in situ hybridization. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:343-7.

https://doi.org/10.1016/j.oooo.2013.06.014

PMid:23953419 

29. Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, et al. Epstein-Barr virus-positive follicular lymphoma. Mod Pathol. 2017;30:519-29.

https://doi.org/10.1038/modpathol.2016.214

PMid:27982024